The dual combination of anti-OX40 and tretinoin significantly improved survival (, p=0.0019 against anti-OX40 and p=0.0090 against tretinoin), with delayed tumour growth compared to either treatment alone (, p<0.001 for both comparisons). This evidence concerns the gene TNFRSF4 and neoplasm.